Literature DB >> 7502727

Stereotactic convergent beam radiosurgery versus stereotactic conformation beam radiotherapy.

G Becker1, W Schlegel, J Major, E H Grote, M Bamberg.   

Abstract

By means of preliminary results in the treatment of patients with acoustic neurinoma the achievable accuracies, dose distributions and time consumption of stereotactic LINAC-based convergent beam radiosurgery are compared to those achieved with fractionated stereotactic conformation beam radiotherapy. Characteristics of both techniques are described. With the Tübingen radiosurgery system a good adaptation of the dose distribution to spherical or oval target volumes with a steep dose gradient was achieved, whereas homogeneity and adaptation of the dose distribution to irregularly shaped targets were better with the Heidelberg conformation technique. The mechanical accuracy of the Tübingen floorstand system was 0.3 mm +/- 0.2 mm, and that of the Heidelberg mask fixation system < 1 mm. Both methods require similar total treatment times. Nine patients were treated by the Tübingen radiosurgery system. The results are compared with 12 patients treated by conformation radiotherapy in Heidelberg. In both patient groups no further tumour growth occurred. Four of 9 single dose treated patients developed side-effects, such as temporary trigeminal and facial paraesthesia hearing deterioration and oedema. In contrast, patients treated by fractionated radiotherapy showed no side-effects. Relating to the short follow-up the results indicate that single dose application has certain drawbacks for special indications. Further studies have to work out which method gives the best treatment results.

Entities:  

Mesh:

Year:  1995        PMID: 7502727     DOI: 10.1007/978-3-7091-9399-0_10

Source DB:  PubMed          Journal:  Acta Neurochir Suppl        ISSN: 0065-1419


  1 in total

1.  Stereotactic fractionated irradiation of optic nerve sheath meningioma: a new treatment alternative.

Authors:  S Pitz; G Becker; U Schiefer; H Wilhelm; B Jeremic; M Bamberg; E Zrenner
Journal:  Br J Ophthalmol       Date:  2002-11       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.